You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 23, 2024

ferriprox Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Ferriprox, and when can generic versions of Ferriprox launch?

Ferriprox is a drug marketed by Chiesi and is included in three NDAs. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has forty-six patent family members in twenty-eight countries.

The generic ingredient in FERRIPROX is deferiprone. There are four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the deferiprone profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Ferriprox

A generic version of ferriprox was approved as deferiprone by TARO on February 8th, 2019.

  Sign Up

Drug patent expirations by year for ferriprox
Drug Prices for ferriprox

See drug prices for ferriprox

Recent Clinical Trials for ferriprox

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Chiesi Canada CorpPhase 4
Hadassah Medical OrganizationPhase 2/Phase 3
SocraTec R&D GmbHPhase 1

See all ferriprox clinical trials

Pharmacology for ferriprox
Drug ClassIron Chelator
Mechanism of ActionIron Chelating Activity
Anatomical Therapeutic Chemical (ATC) Classes for ferriprox
Paragraph IV (Patent) Challenges for FERRIPROX
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
FERRIPROX Tablets deferiprone 500 mg 021825 1 2016-01-29

US Patents and Regulatory Information for ferriprox

ferriprox is protected by seven US patents and six FDA Regulatory Exclusivities.

Patents protecting ferriprox

Delayed release deferiprone tablets and methods of using the same
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD

Delayed release deferiprone tablets and methods of using the same
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD

Delayed release deferiprone tablets and methods of using the same
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Delayed release deferiprone tablets and methods of using the same
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD

Liquid formulation for deferiprone with palatable taste
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD

FDA Regulatory Exclusivity protecting ferriprox

TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO SICKLE CELL DISEASE OR OTHER ANEMIAS
Exclusivity Expiration: ⤷  Sign Up

TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH THALASSEMIA SYNDROMES
Exclusivity Expiration: ⤷  Sign Up

TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN ADULT PATIENTS WITH THALASSEMIA SYNDROMES EXCLUDING ADULT PATIENTS COVERED BY THE INDICATION FOR THALASSEMIA SYNDROMES APPROVED ON OCTOBER 14, 2011
Exclusivity Expiration: ⤷  Sign Up

TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN ADULT AND PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH SICKLE CELL DISEASE OR OTHER ANEMIAS
Exclusivity Expiration: ⤷  Sign Up

TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN ADULT AND PEDIATRIC PATIENTS 8 YEARS OF AGE AND OLDER WITH SICKLE CELL DISEASE OR OTHER ANEMIAS
Exclusivity Expiration: ⤷  Sign Up

TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN PEDIATRIC PATIENTS 8 YEARS OF AGE AND OLDER WITH THALASSEMIA SYNDROMES
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chiesi FERRIPROX deferiprone SOLUTION;ORAL 208030-002 Apr 20, 2018 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Chiesi FERRIPROX deferiprone TABLET;ORAL 212269-001 May 19, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Chiesi FERRIPROX deferiprone SOLUTION;ORAL 208030-001 Sep 9, 2015 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Chiesi FERRIPROX deferiprone TABLET;ORAL 021825-002 Jul 25, 2019 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Chiesi FERRIPROX deferiprone TABLET;ORAL 212269-001 May 19, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Chiesi FERRIPROX deferiprone SOLUTION;ORAL 208030-001 Sep 9, 2015 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ferriprox

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Chiesi FERRIPROX deferiprone TABLET;ORAL 212269-001 May 19, 2020 ⤷  Sign Up ⤷  Sign Up
Chiesi FERRIPROX deferiprone SOLUTION;ORAL 208030-001 Sep 9, 2015 ⤷  Sign Up ⤷  Sign Up
Chiesi FERRIPROX deferiprone SOLUTION;ORAL 208030-002 Apr 20, 2018 ⤷  Sign Up ⤷  Sign Up
Chiesi FERRIPROX deferiprone TABLET;ORAL 021825-002 Jul 25, 2019 ⤷  Sign Up ⤷  Sign Up
Chiesi FERRIPROX deferiprone TABLET;ORAL 021825-001 Oct 14, 2011 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for ferriprox

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Chiesi Farmaceutici S.p.A. Ferriprox deferiprone EMEA/H/C/000236
Ferriprox monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.Ferriprox in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload (mainly cardiac overload) justifies rapid or intensive correction.
Authorised no no no 1999-08-25
Lipomed GmbH Deferiprone Lipomed deferiprone EMEA/H/C/004710
Deferiprone Lipomed monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.Deferiprone Lipomed in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload justifies rapid or intensive correction.
Authorised yes no no 2018-09-19
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for ferriprox

See the table below for patents covering ferriprox around the world.

Country Patent Number Title Estimated Expiration
China 1331971 ⤷  Sign Up
New Zealand 763555 Delayed release deferiprone tablets and methods of using the same ⤷  Sign Up
Israel 153733 USE OF DEFERIPRONE FOR THE PREPARATION OF IRON CHELATING AGENTS ⤷  Sign Up
Germany 60138189 ⤷  Sign Up
World Intellectual Property Organization (WIPO) 0202114 ⤷  Sign Up
Australia 2018357350 Delayed release deferiprone tablets and methods of using the same ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.